SG11202005060YA - Compositions comprising circular polyribonucleotides and uses thereof - Google Patents

Compositions comprising circular polyribonucleotides and uses thereof

Info

Publication number
SG11202005060YA
SG11202005060YA SG11202005060YA SG11202005060YA SG11202005060YA SG 11202005060Y A SG11202005060Y A SG 11202005060YA SG 11202005060Y A SG11202005060Y A SG 11202005060YA SG 11202005060Y A SG11202005060Y A SG 11202005060YA SG 11202005060Y A SG11202005060Y A SG 11202005060YA
Authority
SG
Singapore
Prior art keywords
compositions
circular polyribonucleotides
polyribonucleotides
circular
Prior art date
Application number
SG11202005060YA
Inventor
Morag Helen Stewart
Catherine Cifuentes-Rojas
Ki Young Paek
Avak Kahvejian
Nicholas Mccartney Plugis
Boer Alexandra Sophie De
Erica Gabrielle Weistein
Sebastian Trousil
Original Assignee
Flagship Pioneering Innovations Vi Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations Vi Llc filed Critical Flagship Pioneering Innovations Vi Llc
Publication of SG11202005060YA publication Critical patent/SG11202005060YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202005060YA 2017-12-15 2018-12-14 Compositions comprising circular polyribonucleotides and uses thereof SG11202005060YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762599547P 2017-12-15 2017-12-15
US201862676688P 2018-05-25 2018-05-25
PCT/US2018/065836 WO2019118919A1 (en) 2017-12-15 2018-12-14 Compositions comprising circular polyribonucleotides and uses thereof

Publications (1)

Publication Number Publication Date
SG11202005060YA true SG11202005060YA (en) 2020-06-29

Family

ID=66820668

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005060YA SG11202005060YA (en) 2017-12-15 2018-12-14 Compositions comprising circular polyribonucleotides and uses thereof

Country Status (13)

Country Link
US (8) US20200306286A1 (en)
EP (1) EP3724208A4 (en)
JP (2) JP2021508490A (en)
KR (1) KR20200127152A (en)
CN (1) CN111819185A (en)
AU (2) AU2018385757B2 (en)
BR (1) BR112020011670A2 (en)
CA (1) CA3084824A1 (en)
IL (1) IL275205A (en)
MA (1) MA51155A (en)
MX (1) MX2020006150A (en)
SG (1) SG11202005060YA (en)
WO (1) WO2019118919A1 (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020011670A2 (en) 2017-12-15 2020-11-17 Flagship Pioneering Innovations Vi, Llc. compositions comprising circular polyribonucleotides and their uses
MX2020013236A (en) 2018-06-06 2021-02-22 Massachusetts Inst Technology Circular rna for translation in eukaryotic cells.
KR20210135265A (en) 2019-03-04 2021-11-12 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 Circular polyribonucleotides and pharmaceutical compositions thereof
CN111718929B (en) * 2019-03-20 2022-10-18 中国科学院上海营养与健康研究所 Protein translation using circular RNA and uses thereof
EP3946466A2 (en) 2019-03-25 2022-02-09 Flagship Pioneering Innovations VI, LLC Compositions comprising modified circular polyribonucleotides and uses thereof
BR112021023411A2 (en) * 2019-05-22 2022-02-01 Massachusetts Inst Technology Compositions and methods of circular rna
WO2020252436A1 (en) 2019-06-14 2020-12-17 Flagship Pioneering Innovations Vi, Llc Circular rnas for cellular therapy
CA3140594A1 (en) 2019-06-19 2020-12-24 Avak Kahvejian Methods of dosing circular polyribonucleotides
US20220305128A1 (en) 2019-06-19 2022-09-29 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides for protein modulation and uses thereof
CN112662659B (en) * 2019-10-15 2022-08-19 武汉核圣生物技术有限公司 Universal mRNA in-vitro cyclization method
AU2020397956A1 (en) 2019-12-04 2022-07-07 Orna Therapeutics, Inc. Circular RNA compositions and methods
TW202142689A (en) 2020-01-29 2021-11-16 美商旗艦先鋒創新有限責任公司 Compositions for translation and methods of use thereof
EP4096681A1 (en) 2020-01-29 2022-12-07 Flagship Pioneering Innovations VI, LLC Delivery of compositions comprising circular polyribonucleotides
EP4121453A2 (en) * 2020-03-20 2023-01-25 Orna Therapeutics, Inc. Circular rna compositions and methods
CA3179423A1 (en) * 2020-05-19 2021-11-25 Robert Alexander WESSELHOEFT Circular rna compositions and methods
CA3179420A1 (en) 2020-05-20 2021-11-25 Avak Kahvejian Coronavirus antigen compositions and their uses
EP4153152A1 (en) 2020-05-20 2023-03-29 Flagship Pioneering Innovations VI, LLC Compositions and methods for producing human polyclonal antibodies
JP2023526423A (en) 2020-05-20 2023-06-21 フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー Immunogenic compositions and uses thereof
CN111733243A (en) * 2020-06-29 2020-10-02 中山大学孙逸仙纪念医院 Method for improving accuracy of CircRNA detection
IL299261A (en) * 2020-07-01 2023-02-01 Elevatebio Tech Inc Compositions and methods for cellular reprogramming using circular rna
CA3191433A1 (en) 2020-08-12 2022-02-17 Actym Therapeutics, Inc. Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
WO2022051629A1 (en) 2020-09-03 2022-03-10 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
EP4267157A1 (en) 2020-12-23 2023-11-01 Flagship Pioneering Innovations V, Inc. In vitro assembly of anellovirus capsids enclosing rna
CN112562788B (en) * 2020-12-28 2022-06-28 上海交通大学 Construction method of circular RNA-RNA binding protein relation prediction model
EP4116421A1 (en) 2021-03-10 2023-01-11 Rznomics Inc. Self-circularized rna structure
AR125216A1 (en) 2021-03-26 2023-06-28 Flagship Pioneering Innovations Vii Llc PRODUCTION OF CIRCULAR POLYRIBONUCLEOTIDES IN A EUKARYOTA SYSTEM
EP4314281A1 (en) 2021-03-26 2024-02-07 Flagship Pioneering Innovations VII, LLC Production of circular polyribonucleotides in a eukaryotic system
TW202305130A (en) 2021-03-26 2023-02-01 美商旗艦先鋒創新有限責任(Vii)公司 Production of circular polyribonucleotides in a prokaryotic system
US20220325287A1 (en) 2021-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
KR20240026921A (en) 2021-05-18 2024-02-29 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 Method for concentrating circular polyribonucleotides
JP2024521304A (en) 2021-05-18 2024-05-31 フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー Method for concentrating circular polyribonucleotides
WO2023288288A1 (en) 2021-07-15 2023-01-19 Turn Biotechnologies, Inc. Synthetic, persistent rna constructs with on/off mechanism for controlled expression and methods of use
WO2023288287A2 (en) * 2021-07-15 2023-01-19 Turn Biotechnologies, Inc. Synthetic, persistent rna constructs and methods of use for cell rejuvenation and for treatment
CN117916371A (en) 2021-07-27 2024-04-19 旗舰创业创新第六有限责任公司 Apparatus, system and method for processing
WO2023044333A1 (en) 2021-09-14 2023-03-23 Renagade Therapeutics Management Inc. Cyclic lipids and methods of use thereof
CA3231523A1 (en) 2021-09-14 2023-03-23 Renagade Therapeutics Management Inc. Acyclic lipids and methods of use thereof
TW202330916A (en) 2021-09-17 2023-08-01 美商旗艦先鋒創新有限責任公司 Compositions and methods for producing circular polyribonucleotides
AU2022370530A1 (en) 2021-10-18 2024-05-02 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
WO2023073228A1 (en) * 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
WO2023086796A2 (en) 2021-11-09 2023-05-19 Actym Therapeutics, Inc. Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment
CA3239266A1 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovations Vi, Llc Coronavirus immunogen compositions and their uses
CA3238735A1 (en) 2021-11-24 2023-06-01 Jennifer A. Nelson Immunogenic compositions and their uses
AU2022397292A1 (en) 2021-11-24 2024-05-30 Flagship Pioneering Innovations Vi, Llc Varicella-zoster virus immunogen compositions and their uses
KR102488280B1 (en) * 2021-11-25 2023-01-16 주식회사 뉴클릭스바이오 Novel splint DNA and use thereof
AR128002A1 (en) 2021-12-17 2024-03-20 Flagship Pioneering Innovations Vi Llc CIRCULAR RNA ENRICHMENT METHODS UNDER DENATURALING CONDITIONS
WO2023122745A1 (en) 2021-12-22 2023-06-29 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
WO2023122752A1 (en) 2021-12-23 2023-06-29 Renagade Therapeutics Management Inc. Constrained lipids and methods of use thereof
WO2023122789A1 (en) 2021-12-23 2023-06-29 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides encoding antifusogenic polypeptides
WO2023143541A1 (en) * 2022-01-28 2023-08-03 Beijing Changping Laboratory Circular rna vaccines and methods of use thereof
WO2023196931A1 (en) 2022-04-07 2023-10-12 Renagade Therapeutics Management Inc. Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
US20240042021A1 (en) 2022-08-01 2024-02-08 Flagship Pioneering Innovations Vii, Llc Immunomodulatory proteins and related methods
KR20240034676A (en) 2022-09-06 2024-03-14 알지노믹스 주식회사 Construct of self-circularization RNA
WO2024054047A1 (en) 2022-09-06 2024-03-14 알지노믹스 주식회사 Self-circularization rna structure
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024097664A1 (en) 2022-10-31 2024-05-10 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
WO2024102799A1 (en) 2022-11-08 2024-05-16 Flagship Pioneering Innovations Vi, Llc Compositions and methods for producing circular polyribonucleotides
WO2024129988A1 (en) 2022-12-14 2024-06-20 Flagship Pioneering Innovations Vii, Llc Compositions and methods for delivery of therapeutic agents to bone
KR102581491B1 (en) * 2023-01-20 2023-09-25 한국과학기술원 A composition comprising RNA with lariat cap structure that enhance intracellular stability and translation of mRNA, and use thereof

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266684A (en) 1988-05-02 1993-11-30 The Reagents Of The University Of California Peptide mixtures
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0542874A4 (en) 1990-07-25 1994-05-11 Syngene Inc Circular extension for generating multiple nucleic acid complements
US5426180A (en) 1991-03-27 1995-06-20 Research Corporation Technologies, Inc. Methods of making single-stranded circular oligonucleotides
US5877160A (en) 1991-05-31 1999-03-02 Genta Incorporated Compositions and methods of treatment of androgen-associated baldness using antisense oligomers
CA2118806A1 (en) 1991-09-18 1993-04-01 William J. Dower Method of synthesizing diverse collections of oligomers
US5639603A (en) 1991-09-18 1997-06-17 Affymax Technologies N.V. Synthesizing and screening molecular diversity
CA2127461A1 (en) 1992-01-13 1993-07-22 Michael D. Been Enzymatic rna molecules
US5541061A (en) 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
DE59309571D1 (en) 1992-08-04 1999-06-17 Thomson Brandt Gmbh High voltage line transformer for a television receiver
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5565324A (en) 1992-10-01 1996-10-15 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5721099A (en) 1992-10-01 1998-02-24 Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5773244A (en) 1993-05-19 1998-06-30 Regents Of The University Of California Methods of making circular RNA
US5440016A (en) 1993-06-18 1995-08-08 Torrey Pines Institute For Molecular Studies Peptides of the formula (KFmoc) ZZZ and their uses
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5688997A (en) 1994-05-06 1997-11-18 Pharmacopeia, Inc. Process for preparing intermediates for a combinatorial dihydrobenzopyran library
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5463564A (en) 1994-09-16 1995-10-31 3-Dimensional Pharmaceuticals, Inc. System and method of automatically generating chemical compounds with desired properties
US5688696A (en) 1994-12-12 1997-11-18 Selectide Corporation Combinatorial libraries having a predetermined frequency of each species of test compound
DK0839152T3 (en) 1995-06-21 2002-07-08 Martek Biosciences Corp Combinatorial libraries of labeled biochemical compounds and processes for their preparation
US5766903A (en) * 1995-08-23 1998-06-16 University Technology Corporation Circular RNA and uses thereof
CA2158237A1 (en) 1995-09-13 1997-03-14 Paolo Favaretto Chair with a pivoting backrest
US5731423A (en) 1996-03-21 1998-03-24 Transcell Technologies, Inc. Process for preparing sulfoxides
US6429301B1 (en) 1998-04-17 2002-08-06 Whitehead Institute For Biomedical Research Use of a ribozyme to join nucleic acids and peptides
US6210931B1 (en) 1998-11-30 2001-04-03 The United States Of America As Represented By The Secretary Of Agriculture Ribozyme-mediated synthesis of circular RNA
AUPR604101A0 (en) 2001-06-29 2001-07-26 Unisearch Limited Aptamers
DE10132780A1 (en) * 2001-07-06 2003-01-16 Icon Genetics Ag Plastid gene expression via autonomously replicating vectors
EP2385123B1 (en) 2001-09-28 2018-04-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microrna molecules
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US20050069938A1 (en) * 2003-09-26 2005-03-31 Youxiang Wang Amplification of polynucleotides by rolling circle amplification
US8084599B2 (en) 2004-03-15 2011-12-27 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
WO2007145612A1 (en) * 2005-06-06 2007-12-21 454 Life Sciences Corporation Paired end sequencing
EP1917357A2 (en) 2005-08-01 2008-05-07 Purdue Research Foundation Multivalent rna nanoparticles for delivery of active agents to a cell
DE102005046490A1 (en) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz New nucleic acid molecule comprising promoter, a transcriptable nucleic acid sequence, a first and second nucleic acid sequence for producing modified RNA with transcriptional stability and translational efficiency
JP5296328B2 (en) 2007-05-09 2013-09-25 独立行政法人理化学研究所 Single-stranded circular RNA and method for producing the same
AU2009336191B2 (en) 2008-12-18 2017-08-24 Dicerna Pharmaceuticals, Inc. Extended dicer substrate agents and methods for the specific inhibition of gene expression
WO2010084371A1 (en) 2009-01-26 2010-07-29 Mitoprod Novel circular interfering rna molecules
WO2010093788A2 (en) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Multiplex dicer substrate rna interference molecules having joining sequences
KR101938548B1 (en) 2011-06-23 2019-01-15 (주)아모레퍼시픽 Composition for regulating expression of pigmentation-related genes containing microRNA
WO2013053481A1 (en) 2011-10-11 2013-04-18 Secutech International Pte. Ltd. Dimethyl sulfoxide as solvent for nucleic acids
WO2013113326A1 (en) * 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
JP6284181B2 (en) * 2012-02-09 2018-02-28 国立研究開発法人理化学研究所 Method for producing circular RNA and protein
EP2833892A4 (en) 2012-04-02 2016-07-20 Moderna Therapeutics Inc Modified polynucleotides for the production of oncology-related proteins and peptides
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
WO2013151666A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of biologics and proteins associated with human disease
PT2800811T (en) 2012-05-25 2017-08-17 Univ California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
WO2014082644A1 (en) 2012-11-30 2014-06-05 WULFF, Peter, Samuel Circular rna for inhibition of microrna
US20160022840A1 (en) 2013-03-09 2016-01-28 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
DE102013005361A1 (en) 2013-03-28 2014-10-02 Eberhard Karls Universität Tübingen Medizinische Fakultät polyribonucleotide
WO2014186334A1 (en) 2013-05-15 2014-11-20 Robert Kruse Intracellular translation of circular rna
JP2016528897A (en) 2013-08-16 2016-09-23 ラナ セラピューティクス インコーポレイテッド Compositions and methods for modulating RNA
US20160194368A1 (en) * 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
EP3058082A4 (en) * 2013-10-18 2017-04-26 ModernaTX, Inc. Compositions and methods for tolerizing cellular systems
BR112016024644A2 (en) 2014-04-23 2017-10-10 Modernatx Inc nucleic acid vaccines
AU2015289656A1 (en) * 2014-07-16 2017-02-16 Modernatx, Inc. Circular polynucleotides
EP3054017A1 (en) 2015-02-03 2016-08-10 Johann Wolfgang Goethe-Universität, Frankfurt am Main Circular RNA for the diagnosis and treatment of cardiovascular diseases
US10227594B2 (en) 2015-03-20 2019-03-12 Conopco, Inc. Antiperspirant composition
US11000547B2 (en) 2015-06-05 2021-05-11 Dana-Farber Cancer Institute, Inc. Compositions related to rna in circularized form
DK3317411T3 (en) * 2015-06-30 2021-03-15 Ethris Gmbh ATP BINDING CASSETTE FAMILY ENCODING POLYRIBONUCLEOTIDES AND FORMULATIONS THEREOF
JP2018526007A (en) * 2015-09-04 2018-09-13 トカジェン インコーポレーテッド Recombinant vector containing 2A peptide
AU2017280943B2 (en) 2016-06-20 2023-05-18 Emory University Circular RNAs and their use in immunomodulation
CN106222174B (en) * 2016-08-12 2020-08-04 青岛大学 Use of circRNA CHIF nucleotides in the treatment of cardiac disorders
US11753434B2 (en) 2017-04-14 2023-09-12 Dana-Farber Cancer Institute, Inc. Compositions and methods for transient gene therapy with enhanced stability
US11756183B2 (en) 2017-06-23 2023-09-12 Cornell University RNA molecules, methods of producing circular RNA, and treatment methods
BR112020011670A2 (en) 2017-12-15 2020-11-17 Flagship Pioneering Innovations Vi, Llc. compositions comprising circular polyribonucleotides and their uses
MX2020013236A (en) 2018-06-06 2021-02-22 Massachusetts Inst Technology Circular rna for translation in eukaryotic cells.
CA3107683A1 (en) 2018-07-24 2020-01-30 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
CN111603477B (en) 2019-02-25 2023-06-02 中国科学院分子细胞科学卓越创新中心 Application of annular RNA in preparation of therapeutic drugs for systemic lupus erythematosus
WO2020180752A1 (en) 2019-03-01 2020-09-10 Flagship Pioneering Innovations Vi, Llc Polyribonucleotides and cosmetic uses thereof
KR20210134716A (en) 2019-03-01 2021-11-10 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 Compositions, methods, and kits for the delivery of polyribonucleotides
KR20210135265A (en) 2019-03-04 2021-11-12 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 Circular polyribonucleotides and pharmaceutical compositions thereof
EP3946466A2 (en) 2019-03-25 2022-02-09 Flagship Pioneering Innovations VI, LLC Compositions comprising modified circular polyribonucleotides and uses thereof
WO2020252436A1 (en) 2019-06-14 2020-12-17 Flagship Pioneering Innovations Vi, Llc Circular rnas for cellular therapy
CA3140594A1 (en) 2019-06-19 2020-12-24 Avak Kahvejian Methods of dosing circular polyribonucleotides
US20220305128A1 (en) 2019-06-19 2022-09-29 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides for protein modulation and uses thereof
EP4096681A1 (en) 2020-01-29 2022-12-07 Flagship Pioneering Innovations VI, LLC Delivery of compositions comprising circular polyribonucleotides
WO2021155177A1 (en) 2020-01-29 2021-08-05 Flagship Pioneering Innovations Vi, Llc Compositions comprising linear polyribonucleotides for protein modulation and uses thereof
TW202142689A (en) 2020-01-29 2021-11-16 美商旗艦先鋒創新有限責任公司 Compositions for translation and methods of use thereof
CA3179420A1 (en) 2020-05-20 2021-11-25 Avak Kahvejian Coronavirus antigen compositions and their uses
EP4153152A1 (en) 2020-05-20 2023-03-29 Flagship Pioneering Innovations VI, LLC Compositions and methods for producing human polyclonal antibodies
JP2023526423A (en) 2020-05-20 2023-06-21 フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー Immunogenic compositions and uses thereof

Also Published As

Publication number Publication date
AU2018385757B2 (en) 2023-10-19
AU2024200298A1 (en) 2024-02-01
IL275205A (en) 2020-07-30
MX2020006150A (en) 2020-11-11
JP2023126888A (en) 2023-09-12
EP3724208A1 (en) 2020-10-21
AU2018385757A1 (en) 2020-06-25
US20230070937A1 (en) 2023-03-09
US20230201241A1 (en) 2023-06-29
US10953033B2 (en) 2021-03-23
US11160822B2 (en) 2021-11-02
CN111819185A (en) 2020-10-23
MA51155A (en) 2020-10-21
US11058706B2 (en) 2021-07-13
US20210275565A1 (en) 2021-09-09
KR20200127152A (en) 2020-11-10
US20190307785A1 (en) 2019-10-10
BR112020011670A2 (en) 2020-11-17
US20200306286A1 (en) 2020-10-01
JP2021508490A (en) 2021-03-11
WO2019118919A1 (en) 2019-06-20
US11458156B2 (en) 2022-10-04
US11844759B2 (en) 2023-12-19
US20240122959A1 (en) 2024-04-18
EP3724208A4 (en) 2021-09-01
US20220023331A1 (en) 2022-01-27
US20210161938A1 (en) 2021-06-03
CA3084824A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
IL275205A (en) Compositions comprising circular polyribonucleotides and uses thereof
IL280354A (en) Compositions comprising circular polyribonucleotides and uses thereof
GB2564307B (en) Foam compositions and uses thereof
HK1251922A1 (en) Antimicrobial compositions and uses thereof
IL271275A (en) Compositions comprising curons and uses thereof
IL268970A (en) Novel compositions and methods
IL286621A (en) Compositions comprising modified circular polyribonucleotides and uses thereof
ZA201702213B (en) Interleukin-15 compositions and uses thereof
ZA201803875B (en) Interleukin-15 compositions and uses thereof
HUE065174T2 (en) Hla-based methods and compositions and uses thereof
IL267925B (en) Hsd17b13 variants and uses thereof
GB201807325D0 (en) Compositions and methods
GB202201860D0 (en) Novel methods and compositions
GB201502002D0 (en) Uses and compositions
GB201608762D0 (en) Compositions and uses thereof
GB202004930D0 (en) Composition and uses thereof
GB201502026D0 (en) Uses and compositions
GB201501991D0 (en) Uses and compositions
ZA202004533B (en) Skin-brightening compositions and methods
GB201712592D0 (en) Novel compositions and uses thereof
GB201614897D0 (en) Compositions and uses thereof
GB201602409D0 (en) Compositions and uses thereof
GB201522814D0 (en) Compositions and uses thereof
GB201511886D0 (en) Uses and compositions
GB201812952D0 (en) Compositions and uses thereof